These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

151 related items for PubMed ID: 11819156

  • 1. Neuroleptic malignant syndrome in a patient with succinic semialdehyde dehydrogenase deficiency.
    Neu P, Seyfert S, Brockmöller J, Dettling M, Marx P.
    Pharmacopsychiatry; 2002 Jan; 35(1):26-8. PubMed ID: 11819156
    [Abstract] [Full Text] [Related]

  • 2. The role of CYP2D6 and TaqI A polymorphisms in malignant neuroleptic syndrome: two case reports with three episodes.
    Zivković M, Mihaljević-Peles A, Sagud M, Silić A, Mihanović M.
    Psychiatr Danub; 2010 Mar; 22(1):112-6. PubMed ID: 20305604
    [Abstract] [Full Text] [Related]

  • 3. Haloperidol-induced neuroleptic malignant syndrome complicated by hyperosmolar hyperglycemic state.
    Rock W, Elias M, Lev A, Saliba WR.
    Am J Emerg Med; 2009 Oct; 27(8):1018.e1-3. PubMed ID: 19857430
    [Abstract] [Full Text] [Related]

  • 4. A case study: neuroleptic malignant syndrome with risperidone and CYP2D6 gene variation.
    Ochi S, Kawasoe K, Abe M, Fukuhara R, Sonobe K, Kawabe K, Ueno S.
    Gen Hosp Psychiatry; 2011 Oct; 33(6):640.e1-2. PubMed ID: 21749835
    [Abstract] [Full Text] [Related]

  • 5. CYP2D6 gene deletion allele in patients with neuroleptic malignant syndrome: preliminary report.
    Kato D, Kawanishi C, Kishida I, Furuno T, Matsumura T, Hasegawa H, Suzuki K, Hirayasu Y.
    Psychiatry Clin Neurosci; 2005 Aug; 59(4):504-7. PubMed ID: 16048458
    [Abstract] [Full Text] [Related]

  • 6. Neuroleptic malignant syndrome with use of quetiapine in mental retardation.
    Dan A, Bharadwaj R, Grover S.
    Psychiatry Clin Neurosci; 2009 Apr; 63(2):255-6. PubMed ID: 19335404
    [No Abstract] [Full Text] [Related]

  • 7. [Neuroleptic malignant syndrome and atypical antipsychotics: a brief review].
    Khaldi S, Kornreich C, Choubani Z, Gourevitch R.
    Encephale; 2008 Dec; 34(6):618-24. PubMed ID: 19081460
    [Abstract] [Full Text] [Related]

  • 8. Neuroleptic malignant syndrome in a man with mental retardation.
    McNally RJ, Calamari JE.
    Ment Retard; 1988 Dec; 26(6):385-6. PubMed ID: 3237069
    [No Abstract] [Full Text] [Related]

  • 9. Neuroleptic malignant syndrome: three episodes with different drugs.
    Lavie CJ, Ventura HO, Walker G.
    South Med J; 1986 Dec; 79(12):1571-3. PubMed ID: 2878496
    [Abstract] [Full Text] [Related]

  • 10. Neuroleptic malignant syndrome and mental retardation: review and analysis of 29 cases.
    Boyd RD.
    Am J Ment Retard; 1993 Jul; 98(1):143-55. PubMed ID: 8103996
    [Abstract] [Full Text] [Related]

  • 11. Neuroleptic malignant syndrome precipitated by haloperidol following clozapine discontinuation.
    Mendhekar DN, Jiloha RC.
    Aust N Z J Psychiatry; 2005 Oct; 39(10):947-8. PubMed ID: 16168023
    [No Abstract] [Full Text] [Related]

  • 12. Recurrence of neuroleptic malignant syndrome via an inadvertent rechallenge in a woman with mental retardation.
    Boyd RD.
    Ment Retard; 1992 Apr; 30(2):77-9. PubMed ID: 1584031
    [Abstract] [Full Text] [Related]

  • 13. Vigabatrin and newer interventions in succinic semialdehyde dehydrogenase deficiency.
    Gropman A.
    Ann Neurol; 2003 Apr; 54 Suppl 6():S66-72. PubMed ID: 12891656
    [Abstract] [Full Text] [Related]

  • 14. Cytochrome P450 2D6 deficiency and its clinical relevance in a patient treated with risperidone.
    Köhnke MD, Griese EU, Stösser D, Gaertner I, Barth G.
    Pharmacopsychiatry; 2002 May; 35(3):116-8. PubMed ID: 12107857
    [Abstract] [Full Text] [Related]

  • 15. Depot haloperidol treatment in outpatients with schizophrenia on monotherapy: impact of CYP2D6 polymorphism on pharmacokinetics and treatment outcome.
    Panagiotidis G, Arthur HW, Lindh JD, Dahl ML, Sjöqvist F.
    Ther Drug Monit; 2007 Aug; 29(4):417-22. PubMed ID: 17667795
    [Abstract] [Full Text] [Related]

  • 16. Adverse effects of summer amongst people with learning disabilities: neuroleptic malignant syndrome.
    Fitzgerald B, Middleton JK, Cooper SA.
    J Intellect Disabil Res; 1997 Jun; 41 ( Pt 3)():273-7. PubMed ID: 9219078
    [Abstract] [Full Text] [Related]

  • 17. [Lethal catatonia and its differential diagnosis with the neuroleptic malignant syndrome].
    Andreu Giménez L, Robert Gates J, Jover Díaz F, Pagán Acosta G, Merino Sánchez J.
    Rev Neurol; 1997 Jun; 34(4):399-400. PubMed ID: 12022063
    [No Abstract] [Full Text] [Related]

  • 18. "Atypical" neuroleptic malignant syndrome and the spectrum of malignant cerebrotoxic syndromes.
    Choi-Kain LW, Pope HG.
    Harv Rev Psychiatry; 2007 Jun; 15(4):181-6. PubMed ID: 17687712
    [No Abstract] [Full Text] [Related]

  • 19. Neuroleptic malignant syndrome: an experience of four cases.
    Desai ND, Mundra VK, Gore YS, Diwan PJ, Jaydeokar SS, Jain V, Sutharsan R, Agarwal A, Moulick ND, Manocha SM.
    J Assoc Physicians India; 1998 Jul; 46(7):653-4. PubMed ID: 12152854
    [Abstract] [Full Text] [Related]

  • 20. [Neuroleptic malignant syndrome].
    Charra B, Nejmi H, Hachimi A, Benslama A, Motaouakkil S.
    Ann Fr Anesth Reanim; 2006 May; 25(5):542-3. PubMed ID: 16488105
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.